Home › Compare › IUGNF vs FCPT

IUGNF vs FCPT: Dividend Comparison 2026

IUGNF yields 1788.91% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IUGNF wins by $3531675981.96M in total portfolio value
10 years
IUGNF
IUGNF
● Live price
1788.91%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3531675982.01M
Annual income
$3,181,793,952,650,469.00
Full IUGNF calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — IUGNF vs FCPT

📍 IUGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIUGNFFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IUGNF + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IUGNF pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IUGNF
Annual income on $10K today (after 15% tax)
$152,057.25/yr
After 10yr DRIP, annual income (after tax)
$2,704,524,859,752,898.50/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, IUGNF beats the other by $2,704,524,859,747,989.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IUGNF + FCPT for your $10,000?

IUGNF: 50%FCPT: 50%
100% FCPT50/50100% IUGNF
Portfolio after 10yr
$1765837991.03M
Annual income
$1,590,896,976,328,122.20/yr
Blended yield
90.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

IUGNF
No analyst data
Altman Z
-15.4
Piotroski
1/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IUGNF buys
0
FCPT buys
0
No recent congressional trades found for IUGNF or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIUGNFFCPT
Forward yield1788.91% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$3531675982.01M ✓$49.1K
Annual income after 10y$3,181,793,952,650,469.00 ✓$5,775.28
Total dividends collected$3506616114.25M ✓$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: IUGNF vs FCPT ($10,000, DRIP)

YearIUGNF PortfolioIUGNF Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$189,591$178,890.88$11,401$700.92+$178.2K → IUGNF
2$3,372,589$3,169,726.93$13,064$864.84+$3.36M → IUGNF
3$56,305,450$52,696,779.78$15,051$1,072.48+$56.29M → IUGNF
4$882,465,426$822,218,594.62$17,442$1,337.22+$882.45M → IUGNF
5$12,987,684,313$12,043,446,306.47$20,340$1,677.08+$12987.66M → IUGNF
6$179,550,479,073$165,653,656,858.63$23,880$2,116.57+$179550.46M → IUGNF
7$2,332,406,409,977$2,140,287,397,368.80$28,241$2,689.36+$2332406.38M → IUGNF
8$28,479,672,886,997$25,983,998,028,321.59$33,660$3,442.07+$28479672.85M → IUGNF
9$326,992,550,798,860$296,519,300,809,773.56$40,456$4,439.95+$326992550.76M → IUGNF
10$3,531,675,982,005,250$3,181,793,952,650,469.00$49,063$5,775.28+$3531675981.96M → IUGNF

IUGNF vs FCPT: Complete Analysis 2026

IUGNF — Stock

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Full IUGNF Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this IUGNF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IUGNF vs SCHDIUGNF vs JEPIIUGNF vs OIUGNF vs KOIUGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.